PGRMC1 and breast cancer: Another in vitro study revealed that the created Asp120Gly PGRMC1 mutant did not bind heme and caused increased susceptibility of breast cancer cells to doxorubicin and camptothecin, two topoisomerase inhibitors used as chemotherapeutic agents [147].